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0.001]. Moreover, respondents from urban areas were found to have better knowledge 
(12.06 ± 3.82) than rural residents (8.38 ± 4.92, t = 20.0), (P = < 0.001). While, in term 
of level of income those with high income (12.37 ± 3.79) have signiﬁ cantly better 
knowledge than low income (8.00 ± 4.85), [F = 5.5, P < 0.001]. CONCLUSIONS: The 
level of knowledge about TB among TB patients was a low, Therefore, there is a need 
for massive health education campaign to be undertaken by policymakers in order to 
improve TB patients’ knowledge toward TB. 
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OBJECTIVES: The use of long-acting beta agonists (LABAs) has raised safety concerns, 
especially the potential for severe asthma exacerbations (SAEs). The purpose of this 
review was to review the published safety outcomes researches about LABA therapy and 
compare disease epidemiologic trends. METHODS: A systematic literature review was 
conducted with the speciﬁ c focus on safety outcomes research from clinical trials, meta-
analyses, and post-marketing studies. Patients with asthma were reviewed and compared 
between races, and between age groups. SAEs were deﬁ ned as either asthma-related 
death, hospitalization or emergency room visits. Seven major studies were identiﬁ ed and 
reviewed. Annual mortality rate and SAE trends for asthmatic patients and subgroup 
of African American patients were compared. RESULTS: The prevalence of asthma 
increased from 5% in 1992 to 7.8% in 2006, while mortality rate decreased from 1.7 
per 100,000 in 1999 to 1.2 per 100,000 in 2006. Multiple clinical trial data showed 
that LABA monotherapy may be associated with increased risk of asthma exacerbation 
or asthma related death. On the other hand, meta-analyses showed that the use of LABA 
with ICS may be associated with positive outcomes including symptoms reduction, 
quality of life improvement, reduced rate of exacerbations and severe exacerbation. Due 
to the limited data, the relationship between LABAs and an increased risk of severe 
asthma exacerbation is unclear, especially in pediatric and African American patients. 
Due to safety concerns, the US FDA made several label changes to warn the public about 
LABA therapy and has requested more assessments of LABA use in asthma patients. 
CONCLUSIONS: The safety outcomes of the use of LABAs for the asthma treatment 
remain controversial. More well-design research is required to assess the risk of SAEs 
related to LABA therapy in different populations. 
RESPIRATORY-RELATED DISORDERS – Cost Studies
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OBJECTIVES: To estimate the direct out-of-pocket medical costs of treating major 
diseases attributable to smoking in India. METHODS: Indian data on burden of 
smoking related illnesses was compiled on lines of the BENESCO (Beneﬁ ts of smoking 
cessation on outcomes) model by secondary analysis of existing datasets from census 
and National Sample Survey (NSS), 2004. The prevalence of smoking(cigarettes and 
bidis) was estimated by adjusting census projected population data with smoking rate 
found in the National Family & Health Survey–3 (NFHS-3), 2005–2006. Data on age 
and gender-wise disease prevalence and unit cost of treatment of diseases was obtained 
from NSS. A prevalence-based, disease-speciﬁ c approach was used to estimate the 
direct medical costs of treating cancer and other tumors, bronchial asthma, tubercu-
losis, respiratory diseases, hypertension and coronary heart disease attributable to 
smoking. RESULTS: Analysis of data from NFHS–3 estimated that there were 98.2 
million male and 4 million female smokers in India between 15 to 49 years of age. A 
total of 1.1 million hospitalizations and 90.5 million outpatient visits for 6 major 
diseases among adults were attributed to smoking annually. The total annual direct 
out-of-pocket medical cost for treating 6 major diseases was found to be Indian 
National Rupees 198 billion (US$ 4.4b). The total cost attributable to smoking was 
estimated to be INR 46 billion (US$ 1b) (i.e., 23% of the total); INR 33.8 billion 
(US$ 761m) for outpatient care and INR 12.3 billion (US$ 276m) for inpatient care. 
The total annual smoking attributable cost of treatment was highest for heart disease 
at INR 14.5 billion (US$ 327m) followed by bronchial asthma INR 8.8 billion (US$ 
199m) and hypertension INR 8.6 billion (US$ 195m). CONCLUSIONS: The smoking 
epidemic in India is a major preventable public health problem. The direct out-of-
pocket medical costs of treating major diseases attributable to smoking are high. 
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OBJECTIVES: The aim of the current study was to determine the burden of illness 
associated with uncontrolled asthma in both the United States and Japan. METHODS: 
Data were obtained from the 2009 US and 2008 Japan National Health and Wellness 
Surveys (NHWS), cross-sectional Internet-based surveys of adults. Only patients who 
were diagnosed with asthma were included in the analyses. Using the Asthma Control 
Test (ACT), each asthma patient was categorized as having controlled or uncontrolled 
asthma and these groups were compared on health-related quality of life (mental 
component summary (MCS) and physical component summary (PCS) scores of the 
SF-12v2), the number of emergency room (ER) visits, and the number of hospitaliza-
tions controlling for demographics (country, age, gender, ethnicity, income, education) 
and patient characteristics (BMI and Charlson comorbidity index) in multiple regres-
sion and generalized linear models. RESULTS: In Japan, 648 patients (3.2%) were 
diagnosed with asthma while 6481 patients (8.5%) were diagnosed with asthma in 
the United States. Even after adjusting for demographics and patient characteristics, 
those with uncontrolled asthma reported signiﬁ cantly lower levels of MCS scores (M-adj 
= 42.5 vs. 45.9, P < 0.0001). However, not only were PCS scores signiﬁ cantly lower 
among uncontrolled asthma patients (M-adj = 41.7 vs. 47.4, P < 0.0001), but the dif-
ferences between controlled and uncontrolled patients was signiﬁ cantly greater in the 
United States (b = 4.4, P < 0.0001). The number of hospitalizations (M-adj = 0.61 vs. 
0.23, P < 0.0001) and ER visits (M-adj = 0.51 vs. 0.24, P < 0.0001) were both signiﬁ -
cantly higher for those with uncontrolled asthma. The effect on ER visits was signiﬁ -
cantly stronger in the United States than in Japan (b = 8.2, P < 0.01). CONCLUSIONS: 
Although the prevalence of asthma in the United States and uncontrolled asthma was 
greater than that of Japan, uncontrolled asthma patients in both countries exhibited 
a signiﬁ cantly worse health outcome proﬁ le. 
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OBJECTIVES: Appropriate use of combined inhalation therapies for airway disease 
patients is likely to reduce the undesirable health utilization, improve patients’ health-
related quality of life, smooth the decline of pulmonary function and prevent the 
mortality. A secondary data analysis was performed to describe the utilization of two 
types of combined inhaler therapies among the patients diagnosed with airway diseases 
for quality improvement of medical care. METHODS: The claimed administration 
data with visits using two types of combined inhalers (four various dosages and dosage 
forms of Seretide and one Symbicort turbulaler) and the corresponding visits’ diseases 
and demographic information from the 2000-bed medical center afﬁ liated to a medical 
university in Taiwan were retrieved and analyzed. There were up to ﬁ ve diagnoses 
listed in the data set. The descriptive analysis was performed to examine the trends 
of different types of combined inhalers being prescribed for patients diagnosed with 
corresponding airway diseases (i.e., ICD9: 491, 492,493,494,496, 518) in the year of 
2009. RESULTS: Of 2495 patients being prescribed with the combined inhaler thera-
pies (accounted for 9273 total visits), male was dominated (57.7% vs. 42.3%), average 
age was 56.7 ( ± 22.1) year-old and more than 80% were prescribed by the pulmonary 
physicians. Less than 2% had experience of switching inhalers within 1 year. Only 
55.4% were prescribed with coded airway diseases (asthma and COPD accounted for 
25.2% and 21.96%, respectively). Further, 50.6% of them were prescribed with 
inhalers once or twice within 1 year. These prescribing patterns might encounter the 
“drug choice problems.” CONCLUSIONS: The prescribing patters of combined 
inhaler therapies seem problematic in this health setting and need to be examined 
persistently and periodically. To ensure appropriate usages of these inhalers, it is neces-
sary to further study the contributing factors and to investigate the possible resolutions 
to improve the quality of medical care. 
RESPIRATORY-RELATED DISORDERS – Health Care Use & Policy Studies
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OBJECTIVES: To identify differences in health-care utilization by race and Latino 
ethnicity among children with asthma and determine the relative contribution of 
predisposing, enabling, and unobserved factors in explaining these differences. 
METHODS: The California Health Interview Survey (CHIS) is a non-institutionalized 
household survey of California residents conducted bi-annually since 2001. Cross-
sectional survey data were a0nalyzed to identify differences by race and Latino ethnicity 
among children with asthma. After adjustment for sample weights and design effects, 
over 400,000 samples in the 2007 CHIS were calculated for children with asthma. 
Disparities in health-care utilization across all race/ethnicity categories were analyzed 
using multivariate logistic regression and negative binomial regression analysis. 
RESULTS: Mexican children with asthma are over 100% more likely to have an 
emergency room (ER) visit in the previous year (P < 0.04) and 58% less likely to have 
a doctor visit (P < 0.049) compared to White children with asthma after controlling 
for confounding variables. Among ethnicity groups, Latino ethnicity is 72% more 
likely to have an ER visit in the previous year and 38% less likely to have a doctor 
visit compared to non-Latino ethnicity. Negative binomial regression results show that 
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Mexican race is negatively associated with number of doctor visits (P < 0.024). 
CONCLUSIONS: The CHIS database offers an opportunity to investigate the occur-
rence of ER and doctor visits among children with asthma by race and ethnicity. This 
study shows that Mexican children are more likely to have an ER visit and less likely 
to have a doctor visit compared to White children. 
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OBJECTIVES: To evaluate the professional practices and services of the Malaysian 
community pharmacists, using a ‘simulated client’ interview method. The interview 
was carried at two community pharmacists in the state of Penang. METHODS: The 
simulated client (PhD student at the School of Pharmacy, Universiti Sains Malaysia) 
visited two community pharmacists “Pharmacy A” and “Pharmacy B” and asked for 
medications for his and his son’s “viral fever symptoms” respectively. The details were 
documented in a form developed by the researchers. RESULTS: The ﬁ ndings suggested 
a poor professional behavior and dispensing practices among both the pharmacies 
studied. Although, both of them asked the duration of the symptoms, they did not 
ask the age of the patient (s), presence of blood in sputum, previous history of present-
ing medical complaints, past medical history, drug history and smoking status. The 
nature of the sputum was asked only by the pharmacists at pharmacy B. The pharmacy 
A dispensed Tab. Clarithromycin 500 mg, Tab. Paracetamol 500 mg, and Azithromy-
cin powder for suspension 200 mg/5 ml for his son’s viral fever symptoms. The 
pharmacy B dispensed Tab. Cefuroxime 250 mg, Amoxicillin + clavulanic acid powder 
for suspension 125 mg + 31.25 mg/5 ml, Linctus Dextromethorphan + Pro-methacine 
+ Pseudo-ephedrine + Paraben sebagai pengawet, and Tab. Green oats + Sea Buckthom 
+ Stinging Nettle + Tongat Ali + Damiana. The cost of prescription was RM 56.50 
(US$ 16.14) for pharmacy A and RM 129 (US$ 45.15) at pharmacy B. CONCLU-
SIONS: Our ﬁ ndings suggested the need for continuing pharmacy education (CPE) 
programs for the community pharmacists in the country and need for curriculum 
changes incorporating more topics related to community pharmacy practice. Though 
our survey included only two community pharmacies, it can serve as a pilot study for 
future in depth survey encompassing various regions in Malaysia. 
SENSORY SYSTEMS DISORDERS – Clinical Outcomes Studies
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OBJECTIVES: Psoriasis is a chronic immune-mediated inﬂ ammatory disorder and is 
associated with concurrence of other complex disorders. This study aims to describe 
the epidemiology of psoriasis and the prevalence of comorbidities in patients with 
psoriasis in Taiwan. METHODS: Patients who had at least one outpatient visit or 
admission diagnosed with ICD-9-CM code 696.0–1 in the Taiwan National Health 
Insurance (NHI) claims database during 2006 were identiﬁ ed as psoriasis cases. The 
cases were further classiﬁ ed into moderate to severe psoriasis (sPsO) for those who 
had previously received systemic therapy and mild psoriasis (mPsO) for those who 
had not. The cases were matched with controls in a 1:4 ratio from one million beneﬁ -
ciaries in the NHI dataset representing the Taiwan population. Matching variables 
included age, gender and residential area. Prevalence of comorbidities was assessed 
using prevalence relative risk (RR) based upon a Cox proportional regression model. 
RESULTS: The prevalence of psoriasis in the overall population was 2.35‰ (n = 
53,761). Mean age (SD) was 46.2 (± 18.6) and 60% were male. Of the 53,761 psoria-
sis cases, 17.2% (n = 9,265) were the sPsO type.sPsO patients had a signiﬁ cantly 
increased prevalence ratio (RR; [95% conﬁ dence interval ])for hypertension (1.33; 
[1.26, 1.40]), diabetes (1.52; [1.42, 1.63]), hyperglyceridemia (1.56; [1.44, 1.69]), 
heart disease (1.24; [1.14, 1.34]), depression (1.44; [1.23, 1.69]), hepatitis B (1.95; 
[1.44, 2.65]) and hepatitis C (2.19; [1.49, 3.22]). Increased risk of these comorbidities 
was also observed in mPsO patients compared to controls, but with a smaller magni-
tude compared to sPsO. CONCLUSIONS: Psoriasis was associated with a signiﬁ cantly 
increased risk of comorbidities, especially for those patients with moderate to severe 
disease. These health consequences should be taken into consideration when evaluat-
ing the burdens of psoriasis and designing effective treatment plans. 
SENSORY SYSTEMS DISORDERS – Cost Studies
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OBJECTIVES: Several methods have been to estimate costs in economic evaluation 
studies. Different methods may give different values. The magnitudes of difference of 
estimates based on cost-to-charge ratio and diagnosis related group (DRG) methods 
were not much investigated. This study aimed to assess the differences of estimates 
of direct medical cost calculated by cost-to-charge ratio and DRG method using 
Stevens—Johnson syndrome (SJS) and Toxic epidermal necrolysis (TEN) as a case 
study. METHODS: This study was undertaken with retrospective cohort approach 
using electronic databases of a hospital located in the northern part of Thailand. We 
included patients who came to the hospital between January 1, 2003 and December 
31, 2007 and were coded with International Classiﬁ cation of Disease 10th Edition 
(ICD-10) of L51.1 (SJS) or L51.2 (TEN). We used cost-to-charge ratio and DRG 
methods to estimate direct medical cost of SJS/TEN. All cost estimates were converted 
to reference year (2008) using Thai consumer price index in health product sectors. 
RESULTS: One hundred and ﬁ fty-four patients were included. Mean age was 45.3 
years. Fifty-six percent were male and 93% were SJS patients. The mean and median 
direct medical cost estimated by cost-to-charge ratio was US$918 and US$308, respec-
tively. The mean and median values estimated by DRG were much lower with cost of 
US$554 and US$264, respectively. The mean estimate based on cost-to-charge ratio 
was higher than that of DRG by US$364 or 1.65 times. CONCLUSIONS: The cost 
estimates using cost-to-charge ratio and DRG are different. Selection of cost estima-
tions may impact the cost estimates and cost-effectiveness results. Researchers should 
consider the perspective of study while choosing the method used for estimating costs. 
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OBJECTIVES: Psoriasis is a chronic autoimmune disease that affects approximately 
2.4% of the Taiwanese population. However, little is known about its economic 
burdens. This study estimated those burdens for patients with psoriasis in Taiwan. 
METHODS: Patients who had at least one outpatient visit or admission diagnosed 
with ICD-9-CM code 696.0–1 in the Taiwan National Health Insurance (NHI) claims 
database during 2006 were identiﬁ ed as psoriasis cases. They were further classiﬁ ed 
into moderate to severe psoriasis (sPsO) for those who had previously received sys-
temic therapy and mild psoriasis (mPsO) for those who had not. The cases were 
matched with controls in a 1:4 ratio by age, gender and residential area from a rep-
resentative NHI dataset. Differences in health-care utilization between cases and 
controls were assumed to be attributable to psoriasis. NHI costs were assessed based 
on a two-part model: a logistic regression to predict the probability of use of services 
and a generalized linear model to predict utilization for users of services. Out-of-
pocket costs, transportation costs, and productivity loss from patients and caregivers 
were calculated based on face-to-face patient interviews (n = 327) during July 2009 
to March 2010. All costs were reported in 2009 New Taiwan dollars (1 US$ = 31.91 
NT$). RESULTS: The case-control analysis showed that the NHI cost for patients 
with sPsO and mPsO was 2.34 times and 1.58 times the cost of controls, respectively. 
The total cost due to sPsO was NT$56,885 per patient (70%, 18%, and 12% for 
NHI cost, patient out-of-pocket cost, and productivity loss, respectively). For mPsO, 
the total cost was NT$28,573 (56%, 33%, and 11% for NHI cost, patient out-of-
pocket cost and productivity loss, respectively). Total direct and indirect costs of 
psoriasis are estimated to be NT$1.80 billion annually. CONCLUSIONS: Psoriasis is 
associated with a signiﬁ cant economic disease burden in Taiwan. 
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OBJECTIVES: To assess comorbidity, quality of life (QOL), work/productivity loss, 
and medical resource utilization in patients suffer from glaucoma. METHODS: 
Patients’ self-reported data were collected from 2009 National Health and Wellness 
Survey (NHWS). Survey samples represented major urban areas in China. QOL was 
measured by the physical component score (PCS) and mental component score (MCS) 
of the Short Form-12 (SF-12) (mean score of 50 for general population). Loss of work/
productivity was measured by the validated Work Productivity and Activity Impair-
ment (WPAI) instrument. Medical resource utilization (MRU) was measured by 
health-care provider, emergency room (ER) visits and hospitalization in the past 6 
months. Comparisons were made between respondents who were diagnosed glaucoma 
versus respondents without glaucoma (non-glaucoma group). Since glaucoma typically 
affects adult population, respondents with age 35 and above were included in the 
analysis. RESULTS: Of the 7949 survey respondents with age 35 and above, 85 
